Norges Bank
NGNE icon

Norges Bank’s Neurogene NGNE Stock Holding History

Norges Bank’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,287
Closed -$430K – 2148
2017
Q1 		$430K Buy
+1,287
New +$452K ﹤0.01% 2113

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Norges Bank's NGNE Position: Q2 2017 in Review

Norges Bank sold out of Neurogene (NGNE) in Q2 2017, closing a stake of 1,287 shares — an estimated $430K sold.

Norges Bank first reported a position in NGNE in Q1 2017 and held it in 1 quarter. The position peaked at $430K in Q1 2017. 40 funds tracked by Wall St. Rank hold NGNE as of Q2 2017.

  • Norges Bank reported no remaining Neurogene position as of Q2 2017 after selling out during the quarter.
  • Norges Bank sold 1,287 Neurogene shares in Q2 2017, an estimated $430K.
  • Norges Bank first reported a position in Neurogene in Q1 2017 and held it in 1 quarter.
  • Norges Bank's Neurogene position peaked at $430K in Q1 2017.
  • 40 funds tracked by Wall St. Rank held Neurogene as of Q2 2017.

Based on Norges Bank's 13F filing for Q2 2017, filed 2 Aug 2017.